Skip to main content

Pharma News

academics

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Zydus Cadila entity to sell its India focused Animal Health Business to Multiples Alternate Asset Management led consortium

    Zydus Animal Health and Investments Limited  a wholly owned material subsidiary of Cadila Healthcare Limited, has entered into a Business Transfer Agreement (BTA) and other Ancillary Agreements  to sell and transfer its Animal Healthcare Established Markets Undertaking to Multiples Alternate Asset Management led consortium. Zydus AH is the animal health business of ZAHL focused on India and certain other countries.

  • Dr. Reddys Laboratories announces the launch of Ertapenem for Injection in the U.S. Market

    Dr. Reddys Laboratories Ltd announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA).

  • Karnataka warns Cipla and Jubilant of legal action for less supply of Remdesivir

    The Karnataka government served notices to pharmaceutical majors Cipla and Jubilant warning them of legal proceedings for not supplying adequate quantities of Remdesivir injection bottles as directed by the Government of India. In a notice to the pharmaceutical companies, the Principal Secretary in the Revenue department N Manjunatha Prasad said they were ordered to deliver 62,000 vials of Remdesivir injection, but they supplied very less consignment.

  • Government take steps to ramp up availability of Amphotericin B - to fight Mucormycosis

    A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from Mucormycosis, a post COVID complication. The Government of India is therefore engaging with the manufacturers to ramp up production of the drug. The supply position is expected to improve with extra  imports of this drug and  increase in its production domestically.

  • BioArctic receives patent in Japan for new antibodies targeting Alzheimers disease

    BioArctic AB announced today that the Japanese Patent Office (JPO) has allowed the company’s Japanese patent application 2017-083057 for novel antibodies that could be developed into a treatment for Alzheimers disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aβ) and are linked to the company’s project AD1503. BioArctic received a patent in Europe based on the same antibodies in January 2021.

  • Aster DM Healthcare Announces Global Nursing Award Worth USD 250,000

    To recognize the phenomenal contribution of nurses to the healthcare delivery system across the world, Aster DM Healthcare has launched the Aster Guardian Global Nursing Award. This is all the more relevant in the current scenario as they continue to play a pivotal role in delivering care despite the challenges produced by the Covid-19 pandemic, taking care of patients worldwide and risking their lives.

  • Sun Pharma to Make Eli Lillys Baricitinib Drug in India

    Sun Pharma has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company Lilly for expanding access to Lillys drug, baricitinib in India. Sun Pharma will manufacture and distribute the drug in India.

  • U.S. authorises emergency use of Pfizer COVID-19 vaccine for children

    U.S. Food and Drug Administration, FDA, has expanded the Emergency Use Authorization, EUA, for Pfizer COVID-19 vaccine to include individuals 12 to 15 years of age. This is the first COVID-19 vaccine authorized in the U.S. for use in this age group.

  • Study Investigates the Ability of Masimo O3 to Aid in Monitoring Septic Shock ICU Patients and Predicting Mortality

    Masimo announced today the findings of a study published in the Journal of Anesthesia & Clinical Research in which Dr.

  • DCGI approves 2-DG medicine for moderate to severe COVID-19 cases

    The Drugs Controller General of India, DCGI, has given permission for the emergency use of 2 deoxyD-glucose, 2-DG medicine as an adjunct therapy in moderate to severe Covid-19 cases.

    An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.

Subscribe to Pharma News